Wird geladen...
Vulnerable COPD patients with comorbidities: the role of roflumilast
Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms “roflumilast” and “COPD”. Reference c...
Gespeichert in:
| Veröffentlicht in: | Ther Clin Risk Manag |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4242693/ https://ncbi.nlm.nih.gov/pubmed/25429225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S55105 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|